期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 376, 期 3, 页码 536-541出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2008.09.026
关键词
Leptin; Tau; Alzheimer's disease; Insulin; AMPK; AICAR
资金
- National Institute on Aging [SBIR-1R43AGO29670]
- New Jersey Commission on Science and Technology
Leptin is a centrally acting hormone Controlling metabolic pathways. Recently, it was shown that leptin can reduce amyloid beta levels both in vitro and in vivo. Herein, phosphorylation of tau was investigated following treatment of neuronal cells with leptin and insulin. Specifically, phosphorylation of tau at amino acid residues Ser(202), Ser(396) and Ser(404) was monitored in retinoic acid induced, human cell lines: SH-SY5Y and NTera-2. Both hormones induced a concentration- and time-dependent reduction of tau Phosphorylation, and were synergistic at suboptimum concentrations. Importantly, leptin was 300-fold more potent than insulin (IC50L = 46.9 nM vs. IC50I = 13.8 mu M). A central role for AMP-dependent kinase as a mediator of leptin's action is demonstrated by the ability of 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR) to decrease tau phosphorylation, and by blocking leptin in the presence Of Compound C. Thus, leptin, which ameliorates both amyloid beta and tau-related pathological pathways, holds Promise as a novel therapeutic for Alzheimer's disease. (c) 2008 Elsevier Inc. All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据